Aug 27, 2026, 12:50 UTC
argenx completed its acquisition of Forte Biosciences, Inc., adding the anti-CD122 antibody FB102 to its immunology pipeline.
Source:Aug 21, 2026, 06:27 UTC
Argenx announced successful trial results for its biotech product, causing its stock to soar.
Source:Aug 17, 2026, 05:00 UTC
argenx announced positive topline results from the Phase 3 ALKIVIA trial of VYVGART Hytrulo (efgartigimod) in autoimmune myositis, meeting its primary endpoint of mean Total Improvement Score at Week 52 in combined IMNM and DM patients (p=0.0011).
Jul 27, 2026, 05:00 UTC
argenx agreed to acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion.
Jul 23, 2026, 05:41 UTC
Argenx expanded Vyvgart's label in the United States to cover all gMG serotypes during Q2 2026.
Source:Jul 23, 2026, 05:41 UTC
Argenx reported Q2 2026 financial results with Vyvgart sales of $1.516 billion, up 60% year-over-year.
Jun 10, 2026, 13:11 UTC
The FDA expanded the label of argenx's drug Vyvgart to include adult patients with generalized myasthenia gravis regardless of antibody status.
Source: